AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32124625
Drug: Transcutaneous Tibial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous Tibial Nerve Stimulation (TTNS) daily for 3 months
Trial: 34865304
Drug: Metformin (PCOS-M)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (PCOS-M)
Trial: 33536385
Drug: Vonoprazan-based second-line
RxNorm normalized name: vonoprazan
DrugBank: Vonoprazan (DB11739)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Vonoprazan-based second-line therapy
Trial: 33127971
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment in PCOS patients (PCOS-T)
Trial: 35525262
Drug: Conservative strategy
RxNorm normalized name: Conserved dopamine neurotrophic factor
DrugBank: HER-902 (DB17948)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative strategy group (optimal medical therapy with primary PCI not performed)
Trial: 35734811
Drug: Telenursing intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Telenursing intervention (telephone calls twice a week for the first six weeks, then once a week until week 12)
Trial: 33256694
Drug: Specific sensorimotor
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific sensorimotor treatment (SMT)
Trial: 33820711
Drug: Repetitive facilitative
RxNorm normalized name: An adeno-associated virus serotype 9 (AAV9) vector with engineered transgene encoding the human CLN7/MFSD8 gene for expression of active human major facilitator superfamily domain containing 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive facilitative exercise (RFE) and botulinum toxin type A (BoNT‐A) injection
Trial: 34650303
Drug: Topical placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical placebo without Nr‐CWS combined with normal saline
Trial: 35802640
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (FADs and SBC activities).
Trial: 35802640
Drug: Neither treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neither treatment (control group).
Trial: 34050932
Drug: FIASMA medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FIASMA medication
Trial: 34050932
Drug: No FIASMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No FIASMA medication
Trial: 32790036
Drug: Gaze-contingent music
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gaze-contingent music reward therapy (8 sessions)
Trial: 35294545
Drug: Bevacizumab added
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab added to temozolomide treatment
Trial: 35294545
Drug: Temozolomide treatment
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Temozolomide treatment alone (control)
Trial: 35861630
Drug: Canagliflozin 100
RxNorm normalized name: canagliflozin 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin 100 mg once daily for 104 weeks
Trial: 35861630
Drug: Placebo once
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once daily for 104 weeks
Trial: 34880344
Drug: Topical Anesthesia
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Anesthesia (TA) 20% benzocaine
Trial: 35606238
Drug: Endorsement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endorsement of the vaccine from the pictured doctor (Poster M)
Trial: 33427091
Drug: Category 1
RxNorm normalized name: lipase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Category 1 anti-tubercular treatment with additional prednisolone
Trial: 33427091
Drug: Conventional anti-tubercular
RxNorm normalized name: Anti Bac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional anti-tubercular treatment alone (Control)
Trial: 34112063
Drug: Emotion Regulation
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Emotion Regulation Therapy for ICs (ERT‐C)
Trial: 35647184
Drug: High Power
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Power Laser Therapy (HPLT) for 3 weeks
Trial: 35647184
Drug: Conventional physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional physiotherapy program (ultrasound therapy, moist heat pack, and home exercises) for 3 weeks
Trial: 34248142
Drug: Neutralizing antibodies
RxNorm normalized name: DentiCare Neutral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutralizing antibodies
Trial: 34248142
Drug: Small-molecule inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small-molecule inhibitors
Trial: 34248142
Drug: DC vaccines
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DC vaccines
Trial: 34248142
Drug: TLR agonists
RxNorm normalized name: TLR-AD1
DrugBank: TLR-AD1 (DB18241)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TLR agonists
Trial: 32517674
Drug: Prevail Managers
RxNorm normalized name: Prevail Injectable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prevail Managers programme (communication skills, problem formulation, and problem-solving skills)
Trial: 38129117
Drug: Telitacicept 80
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept 80 mg
Trial: 38129117
Drug: Telitacicept 160
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept 160 mg
Trial: 38129117
Drug: Telitacicept 240
RxNorm normalized name: Telitacicept
DrugBank: Telitacicept (DB18312)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept 240 mg
Trial: 35844038
Drug: Telitacicept (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telitacicept (all doses)
Trial: 34377197
Drug: Dexamethasone and
RxNorm normalized name: dexamethasone and antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone and dexmedetomidine combination
Trial: 32812388
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine (0.25 mg/kg diluted to 5 ml with 0.9% saline)
Trial: 32812388
Drug: Placebo (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (5 ml of 0.9% saline)
Trial: 34252374
Drug: Adjuvant CapOx
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant CapOx (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral capecitabine 1000 mg/m2 twice a day)
Trial: 34252374
Drug: Adjuvant SOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day)
Trial: 34252374
Drug: Perioperative SOX
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perioperative SOX (intravenous oxaliplatin 130 mg/m2 on day one of each 21 day cycle plus oral S-1 40-60 mg twice a day for three cycles preoperatively and five cycles postoperatively followed by three cycles of S-1 monotherapy)
Trial: 34119628
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without statin treatment
Trial: 32726529
Drug: RSV fusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: RSV fusion (F) protein nanoparticle vaccine
Trial: 33751401
Drug: IBI301 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI301 plus CHOP (375 mg/m2)
Trial: 33751401
Drug: Rituximab plus
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab plus CHOP (375 mg/m2)
Trial: 32683732
Drug: Relaxation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation therapy in addition to standard dermatology treatment
Trial: 32683732
Drug: Standard dermatology
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dermatology treatment only (Control)
Trial: 33722518
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin A treatment in addition to oral medication (B+ group)
Trial: 33722518
Drug: Oral medication
RxNorm normalized name: Oral Medication Syringe 3mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medication only (B- group)
Trial: 33481179
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium sulfate 1 mL/kg/day for 1 month
Trial: 33481179
Drug: Oral magnesium
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral magnesium sulfate
Trial: 35429739
Drug: Immersive psychosocial
RxNorm normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immersive psychosocial training program and 10-min daily exercise (36 days total; n = 23; depressed at baseline n = 14)
Trial: 39141379
Drug: Vergence/accommodative therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vergence/accommodative therapy
Trial: 36260859
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine (25-μg injections, two doses, administered 28 days apart)
Trial: 36260859
Drug: mRNA-1273 vaccine
RxNorm normalized name: SARS-CoV-2 mRNA-1273 vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mRNA-1273 vaccine (25-μg injections, two doses)
Trial: 34767575
Drug: Blended cognitive-behavioural
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blended cognitive-behavioural therapy (bCBT)
Trial: 34767575
Drug: Face-to-face cognitive-behavioural
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face cognitive-behavioural therapy (ftfCBT)
Trial: 33564849
Drug: Heterogeneity in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heterogeneity in symptoms and treatments
Trial: 34231956
Drug: Conventional freehand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional freehand dental implant placement
Trial: 34231956
Drug: Dynamic computer-aided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dynamic computer-aided implant surgery (CAIS)
Trial: 34231956
Drug: Static computer-aided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Static computer-aided implant surgery (CAIS)
Trial: 32184121
Drug: Cisplatin (CDDP)
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin (CDDP) 40 mg/m2 plus radiation therapy (RT)
Trial: 32184121
Drug: Cetuximab (CTX)
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab (CTX) 250 mg/m2 plus a loading dose of 400 mg/m2 plus radiation therapy (RT)
Trial: 33000390
Drug: Computerized decision
RxNorm normalized name: Precise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computerized decision support alert for anticoagulation prescription
Trial: 33061398
Drug: Low-dose simvastatin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose simvastatin (≤20 mg/day)
Trial: 33061398
Drug: High-dose atorvastatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose atorvastatin (40 mg/day for 6 weeks, then 80 mg/day for 6 weeks)
Trial: 35688116
Drug: Technology group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Technology group (tablet use)
Trial: 32174840
Drug: Salbutamol administration
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol administration
Trial: 32179393
Drug: Ultrasound-guided erector
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided erector spinae plane block (ESPB) with 25 ml of 0.5% ropivacaine
Trial: 33395690
Drug: Environmental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Environmental treatments with diverse microbial communities
Trial: 34665507
Drug: all other
RxNorm normalized name: ALL OTHER THERAPEUTIC PRODUCTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: all other formulations
Trial: 32134129
Drug: Liberal transfusion
RxNorm normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liberal transfusion strategy (RBC top-up transfusion to 12 g/dL)
Trial: 33412339
Drug: Carnoy's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnoy's solution applied for 5 minutes after surgical excision
Trial: 33412339
Drug: Surgical excision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical excision without Carnoy's solution
Trial: 35857811
Drug: Switchers (those
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switchers (those who switched to the other antipsychotic)
Trial: 35857811
Drug: Stayers (those
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stayers (those who remained on the same compound)
Trial: 34120366
Drug: Topiramate treatment
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate treatment
Trial: 35906015
Drug: Persuasive messages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Persuasive messages focusing on vaccine safety
Trial: 33502090
Drug: Empagliflozin (10,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin (10, 25 mg)
Trial: 34260836
Drug: Control therapy
RxNorm normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control therapy (investigator's choice from 10 options)
Trial: 33782244
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline injection in the same level at the control side)
Trial: 36050695
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA)
Trial: 36050695
Drug: 4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 g/day olive oil (placebo)
Trial: 36087395
Drug: Lanreotide autogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanreotide autogel 120 mg (LAN)
Trial: 33978350
Drug: LDA +
RxNorm normalized name: Levodopa and Carbidopa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LDA + L-Arg (3g) + Mg (350 mg) + Sal (100 mg)
Trial: 34244279
Drug: Light therapy
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Light therapy (LT) delivered via a portable device, daily for 30 min at medium intensity for 8 weeks
Trial: 36154518
Drug: Bright White
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright White Light (BWL) therapy at 10,000 lux, applied daily between the second and eighth days of chemotherapy
Trial: 36154518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no BWL therapy)
Trial: 36154518
Drug: Bright White
RxNorm normalized name: PROPOLIS EXTRACT 7 g in 140 g / MENTHA PIPERITA (PEPPERMINT) STEM EXTRACT 1.4 g in 140 g / CHRYSANTHELLUM INDICUM FLOWER OIL 1.4 g in 140 g ORAL PASTE [BARUBT Probiotics Bright White Tooth-Paste]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright White Light (BWL) therapy
Trial: 33916497
Drug: Clinically indicated
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clinically indicated peripheral intravenous replacement (CIPIR)
Trial: 34427681
Drug: Lung cancer
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lung cancer screening with low-dose computed tomography (LDCT)
Trial: 32745092
Drug: Aspirin 81-mg
RxNorm normalized name: aspirin 81 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 81-mg twice daily
Trial: 32745092
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin 30-mg twice daily
Trial: 33938709
Drug: Intralesional Vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Vitamin D3 injection
Trial: 33938709
Drug: Intralesional Candida
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional Candida Albicans Antigen injection
Trial: 34036177
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC) treatment
Trial: 33170239
Drug: Omega-3s (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3s (1 g/d)
Trial: 33860587
Drug: Propolis plus
RxNorm normalized name: propolis
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propolis plus Hyoscyamus niger L. methanolic extract syrup (1.6 mg of extract and 450 mg of propolis per 10 mL, administered three times a day for 6 days)
Trial: 35996188
Drug: No TEAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No TEAS treatment (Control)
Trial: 34061314
Drug: Centhaquine (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centhaquine (0.01 mg/kg) administered in 100 mL of normal saline infusion over 1 h
Trial: 33393377
Drug: Treatment intervention
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment intervention
Trial: 32508141
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of contingency information and fear appeal
Trial: 34034748
Drug: Postprandial triglyceride
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postprandial triglyceride (PTG) concentration during oral fat tolerance testing (OFTT)
Trial: 39513526
Drug: Alkylating agents
RxNorm normalized name: ALKYLATING AGENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alkylating agents
Trial: 36326664
Drug: Treatment Foster
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment Foster Care Oregon (TFCO)
Trial: 35180096
Drug: Manipulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manipulation Therapy (MT)
Trial: 35710235
Drug: Tailored exercise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tailored exercise and manual therapy
Trial: 33673568
Drug: fortified sachet
RxNorm normalized name: fosfomycin
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fortified sachet (vitamin D and calcium) and powdered milk plus periodontal therapy during pregnancy (early PT) (n = 17)
Trial: 34690787
Drug: OV101 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 5 mg QD (n = 8)
Trial: 34690787
Drug: OV101 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 5 mg BID (n = 8)
Trial: 34690787
Drug: OV101 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 5 mg TID (n = 7)
Trial: 34690787
Drug: OV101 (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OV101 (all doses)
Trial: 32545478
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g of cocoa-rich chocolate (99% cocoa) daily for six months
Trial: 35929990
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C (1.5 g/kg/d, intravenously for 3 hours from D1 to D3) plus FOLFOX ± bevacizumab
Trial: 35929990
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C plus FOLFOX ± bevacizumab
Trial: 35929990
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin C plus chemotherapy
Trial: 32479750
Drug: Acetazolamide 125
RxNorm normalized name: acetazolamide 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide 125 mg twice daily
Trial: 33208593
Drug: Higher CysC
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher CysC concentration (≥0.78mg/L) in patients with higher hsCRP concentrations (≥4.8ng/mL)
Trial: 33287642
Drug: Moderate observational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate observational caffeine intake from coffee (121 to 180 mg/day)
Trial: 33287642
Drug: Moderate observational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate observational caffeine intake from coffee (301 to 360 mg/day)
Trial: 32329766
Drug: Intramuscular naloxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular naloxone
Trial: 36419020
Drug: Cognitive-behavioral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral therapy (CBT) for 2 months